Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues

Journal of Medicinal Chemistry

Volumn 42, Issue 13, 1999, Pages 2432-2440

  Bergeron, Raymond J ^a   Wiegand, Jan ^a   McManis, James S ^a   McCosar, Bruce H ^a   Weimar, William R ^a   Brittenham, Gary M ^b   Smith, Richard E ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIHYDRO 2 (2,4 DIHDROXYPHENYL) 4 METHYLTHIAZOLE 4 CARBOXYLIC ACID; 4,5 DIHYDRO 2 (2,4 DIHYDROXYPHENYL)THIAZOLE 4 CARBOXYLIC ACID; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DESFERRITHIOCIN DERIVATIVE; IRON; IRON CHELATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG SAFETY; IRON KINETICS; IRON OVERLOAD; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BILE; CARBOXYLIC ACIDS; CEBUS; HYDROXYLATION; IRON; IRON CHELATING AGENTS; LIGANDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 0033168448     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990058s     Document Type: Article

References (26)

1. Bergeron, R. J. Synthesis and Solution Structures of Microbial Siderophores. Chem. Rev. 1984, 84, 587-602.
2. Raymond, K. N.; Carrano, C. J. Coordination Chemistry and Microbial Iron Transport. Acc. Chem. Res. 1979, 12, 183-190.
3. Neilands, J. B. Microbial Iron Compounds. Annu. Rev. Biochem 1981, 50, 715-731.
4. Bickel, H.; Hall, G. E.; Keller-Schierlein, W.; Prelog, V.; Vischer, E.; Wettstein, A. Metabolic Products of Actinomycetes. XXVII. Constitutional Formula of Ferrioxamine B. Helv. Chim. Acta 1960, 43, 2129-2138.
5. Anderegg, G.; L'Eplattenier, F.; Schwarzenbach, G. Hydroxamate Complexes. III. Iron(III) Exchange Between Sideramines and Complexones. A Discussion of the Formation Constants of the Hydroxamate Complexes. Helv. Chim. Acta 1963, 46, 1409-1422.
6. Propper, R. D.; Cooper, B.; Rufo, R. R.; Nienhuis, A. W.; Anderson, W. F.; Bunn, H. F.; Rosenthal, A.; Nathan, D. G. Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload. N. Engl. J. Med. 1977, 297, 418-423.
7. Aksoy, M.; Seyithanoglu, B. Y.; Bozbora, A. Thalassemia and Desferrioxamine (Desferal) Introductory Remarks, and Clinical Laboratory Observations. In Hypertension, and Iron Chelation in Thalassemia; Aksoy, A., and Birdwood, G. F. B., Eds.; Huber: Berne, Switzerland, 1984; p 11.
8. Graziano, J. H.; Markenson, A.; Miller, D. R.; Chang, H.; Bestak, M.; Meyers, P.; Pisciotto, P.; Rifkind, A. Chelation Therapy in Beta-Thalassemia Major. I. Intravenous and Subcutaneous Deferoxamine. J. Pediatr. 1978, 92, 648-652.
9. Pippard, M. J.; Callender, S. T. The Management of Iron Chelation Therapy. Br. J. Haematol. 1983, 54, 503-507.
10. Olivieri, N. F.; Brittenham, G. M. Iron-Chelating Therapy and the Treatment of Thalassemia. Blood 1997, 89, 739-761.
11. Bergeron, R J.; Streiff, R. R.; Wiegand, J.; Vinson, J. R. T.; Luchetta, G.; Evans, K. M.; Peter, H.; Jenny, H.-B. A Comparative Evaluation of Iron Clearance Models. Ann. N. Y. Acad. Sci. 1990, 612, 378-393.
12. Bergeron, R. J.; Wiegand, J.; Dionis, J. B.; Egli-Karmakka, M.; Frei, J.; Huxley-Tencer, A.; Peter, H. H. Evaluation of Desferrithiocin and its Synthetic Analogues as Orally Effective Iron Chelators. J. Med. Chem. 1991, 34, 2072-2078.
13. Bergeron, R. J.; Liu, C. Z.; McManis, J. S.; Xia, M. X. B.; Algee, S. E.; Wiegand, J. The Desferrithiocin Pharmacophore. J. Med. Chem. 1994, 37, 1411-1417.
14. Bergeron, R. J.; Wiegand, J.; Weimar, W. R.; Vinson, J. R. T.; Bussenius, J.; Yao, G. W.; McManis, J. S. Desazadesmethyldes-ferrithiocin Analogues as Orally Effective Iron Chelators. J. Med. Chem. 1999, 42, 95-108.
15. Bergeron, R. J.; Wiegand, J.; Wollenweber, M.; McManis, J. S.; Algee, S. E.; Ratliff-Thompson, K. Synthesis and Biological Evaluation of Naphthyldesferrithiocin Iron Chelators. J. Med. Chem. 1996, 39, 1575-1581.
16. Bergeron, R. J.; Wiegand, J.; Ratliff-Thompson, K.; Weimar, W. R. The Origin of the Differences in (R)- and (S)-Desmethyldes-ferrithiocin: Iron-Clearing Properties. Ann. N. Y. Acad. Sci. 1998, 850, 202-216.
17. Karmarkar, S. N.; Kelkar, S. L.; Wadia, M. S. A Simple Unusual One-Step Conversion of Aromatic Aldehydes into Nitriles. Synthesis 1985, 510-512.
18. Ryoo, I.-J.; Song, K-S.; Kim, J.-R.; Kim, W.-G.; Koshino, H.; Yoo, I.-D. A New Cytotoxic Phenylthiazoline, 4-Methylaeruginoic Acid, from Streptomyces sp. KCTC 9303. J. Antibiot. 1997, 50, 256-258.
19. Naegeli, H.-U.; Zähner, H. Metabolites of Microorganisms. Part 193. Ferrithiocin. Helv. Chim. Acta 1980, 63, 1400-1406.
20. Bergeron, R. J.; Streiff, R. R.; Creary, E. A.; Daniels, R. D., Jr.; King, W.; Luchetta, G.; Wiegand, J.; Moerker, T.; Peter, H. H. A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues with Desferrioxamine B in a Cebus Monkey Model. Blood 1993, 81, 2166-2173.
21. Bergeron, R. J.; Streiff, R. R.; Wiegand, J.; Luchetta, G.; Creary, E. A.; Peter, H. H. A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-Hydroxypyrid-4-One, 1,2-Diethyl-3-Hydroxypyrid-4-One, and Deferoxamine. Blood 1982, 79, 1882-1890.
22. Wolfe, L. C.; Nicolosi, R. J.; Renaud, M. M.; Finger, J.; Hegsted, M.; Peter, H.; Nathan, D. G. A Non-Human Primate Model for the Study of Oral Iron Chelators. Br. J. Haematol. 1989, 72, 456-461.
23. Gomori, G. Preparation of Buffers for Use in Enzyme Studies. Methods Enzymol. 1955, 1, 138-146.
24. 2-thiazoline-4-carbonyl)-L-lysines] with Antiviral Activity. Ind. J. Chem. 1977, 15B, 255-257.
25. Anderegg, G.; Räber, M. Metal Complex Formation of a New Siderophore Desferrithiocin and of Three Related Ligands. J. Chem. Soc., Chem. Commun. 1990, 1194-1196.
26. Bergeron, R. J.; Wiegand, J.; Brittenham, G. M. HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy. Blood 1998, 91, 1446-1452.